Teva Pharmaceutical's Sales Slump 18% - WSJ
Teva, one of the biggest generic makers, joins the the brand-name club
TEVA stock as EU cites antitrust concerns over multiple sclerosis therapy (NYSE:TEVA) | Seeking Alpha
EU launches antitrust probe against Teva - www.israelhayom.com
EU Probes Teva For Blocking Rivals To Multiple Sclerosis Drug
Teva Pharma Plunges After Two U.S. Copaxone Patents Invalidated | Investor's Business Daily
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | BioSpace
Teva Long-Term Prospects Bright, Despite Headwinds - TipRanks.com
Teva shares rally as FDA approves troubled drugmaker's migraine treatment | The Times of Israel
High-Court-Sides-Teva-Patent
Biogen sues Teva over MS generic
Teva Pharmaceutical Industries Ltd. - Relapsing remitting #MS (RRMS) is the most common form of multiple sclerosis. Learn more about MS in our full infographic https://bit.ly/3fP8jvu #MultipleSclerosis #MSConnections #MS #WorldMSDay | Facebook
Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much | The Motley Fool
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Teva hires ex-Novartis executive to succeed CEO Schultz, HR News, ETHRWorld
Teva reports new Copaxone data in breastfeeding mothers with relapsing multiple sclerosis | Seeking Alpha
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Teva Pharmaceutical Industries Ltd. - How much do you know about multiple sclerosis and its symptoms? View the full infographic to learn more: https://bit.ly/3fjQVjw #MultipleSclerosis #MSConnections #MS #WorldMSDay | Facebook
Skinny labels' at forefront of possible Supreme Court biopharma cases | BioWorld
Teva loses Copaxone patent dispute case to Mylan in UK - Pharmaceutical Business review
Teva, Takeda To Commercialize Multiple Sclerosis Drug - Asian Scientist Magazine
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst | Fierce Pharma
COPAXONE® | Medication to Treat Relapsing Multiple Sclerosis (RMS)
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
NICE reconsiders and agrees to back Roche's Ocrevus in relapsing multiple sclerosis—with strings attached | Fierce Pharma
Teva Posts 2021 Earnings and Puts Opioid Litigation in Rearview Mirror | BioSpace
